Evidence map›Paper›PMID 21753178›Full record

ArticleNeurology2011

Dominant GDAP1 mutations cause predominantly mild CMT phenotypes.

M Zimoń, J Baets, G M Fabrizi, E Jaakkola, D Kabzińska, J Pilch, A B Schindler, D R Cornblath, K H Fischbeck, M Auer-Grumbach and 10 more

Abstract read
In one paragraph

Article in Neurology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 2 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 84 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Axonal Charcot-Marie-Tooth Disease: from Common Pathogenic Mechanisms to Emerging Treatment Opportunities.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021
    Review
  16. Article
  17. Article
  18. Mutations inInternational journal of molecular sciences · 2021
    Article
  19. Review
  20. Impaired Mitochondrial Mobility in Charcot-Marie-Tooth Disease.Frontiers in cell and developmental biology · 2021
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 3 countries.

M ZimońVIB Department of Molecular Genetics, University of Antwerp, Antwerpen, Belgium.
J Baets
G M Fabrizi
E Jaakkola
D Kabzińska
J Pilch
A B Schindler
D R Cornblath
K H Fischbeck
M Auer-Grumbach
C Guelly
N Huber
E De Vriendt
V Timmerman
U Suter
I Hausmanowa-Petrusewicz
A Niemann
A Kochański
P De Jonghe
A Jordanova
University of Antwerp · BENational Institutes of Health · USUniversity of Oulu · FI

Funding

Studies Of Hereditary Neurological Disease: Disease Gene IdentificationZIANS002974 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI FISCHBECK, KENNETH · 2009 to 2023
$9.8M
Austrian Science Fund FWF P 19455
6 · The paper itself

Abstract

objectiveGanglioside-induced differentiation associated-protein 1 (GDAP1) mutations are commonly associated with autosomal recessive Charcot-Marie-Tooth (ARCMT) neuropathy; however, in rare instances, they also lead to autosomal dominant Charcot-Marie-Tooth (ADCMT). We aimed to investigate the frequency of disease-causing heterozygous GDAP1 mutations in ADCMT and their associated phenotype.

methodsWe performed mutation analysis in a large cohort of ADCMT patients by means of bidirectional sequencing of coding regions and exon-intron boundaries of GDAP1. Intragenic GDAP1 deletions were excluded using an allele quantification assay. We confirmed the pathogenic character of one sequence variant by in vitro experiments assaying mitochondrial morphology and function.

resultsIn 8 Charcot-Marie-Tooth disease (CMT) families we identified 4 pathogenic heterozygous GDAP1 mutations, 3 of which are novel. Three of the mutations displayed reduced disease penetrance. Disease onset in the affected individuals was variable, ranging from early childhood to adulthood. Disease progression was slow in most patients and overall severity milder than typically seen in autosomal recessive GDAP1 mutations. Electrophysiologic changes are heterogeneous but compatible with axonal neuropathy in the majority of patients.

conclusionsWith this study, we broaden the phenotypic and genetic spectrum of autosomal dominant GDAP1-associated neuropathies. We show that patients with dominant GDAP1 mutations may display clear axonal CMT, but may also have only minimal clinical and electrophysiologic abnormalities. We demonstrate that cell-based functional assays can be reliably used to test the pathogenicity of unknown variants. We discuss the implications of phenotypic variability and the reduced penetrance of autosomal dominant GDAP1 mutations for CMT diagnostic testing and counseling.

Indexed as

AnimalsAxonsCharcot-Marie-Tooth DiseaseChlorocebus aethiopsCohort StudiesCOS CellsDNA Mutational AnalysisExonsGenes, DominantHaplotypesHeLa CellsHumansIntronsMitochondriaMutationNerve Tissue ProteinsGDAP proteinNerve Tissue Proteins

Identifiers

PMID21753178
PMCPMC3272385
OpenAlexW2098023814

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.